Phaseline

Companies › 4Moving Biotech

4Moving Biotech: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Immunology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Liraglutide
Glucagon-like peptide 1 receptor agonist
GLP1RPhase 2Knee Osteoarthritis–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07225829LiraglutidePhase 2Knee OsteoarthritisImmunologyAug 2026

Targets

GLP1R (1)

Companies with the same targets

Eli Lilly Novo Nordisk Roche Hangzhou Sciwind Biosciences Hangzhou Zhongmei Huadong Pharmaceutical Hanmi Pharmaceutical Company AstraZeneca Amgen Regeneron Pharmaceuticals Green Valley (Shanghai) Pharmaceuticals

Companies built like this

Aravax VivaTech International AltruBio Qu Biologics Bluefin Biomedicine

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.